1/49
Looks like no tags are added yet.
Prevention Levels — Primary, Secondary and Tertiary
𝗣𝗿𝗶𝗺𝗮𝗿𝘆 — 𝗯𝗲𝗳𝗼𝗿𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲: Prevents disease or exposure; vaccination, breastfeeding, nutrition, vitamins, hygiene, avoiding smoking. 𝗦𝗲𝗰𝗼𝗻𝗱𝗮𝗿𝘆 — 𝗲𝗮𝗿𝗹𝘆 𝗱𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻: Identifies and treats disease early; newborn PKU screening, blood tests, BP measurements, imaging. 𝗧𝗲𝗿𝘁𝗶𝗮𝗿𝘆 — 𝗮𝗳𝘁𝗲𝗿 𝗱𝗶𝘀𝗲𝗮𝘀𝗲: Reduces disability, complications and loss of function; physiotherapy or rehabilitation after meningitis-related neurological injury. 𝗞𝗲𝘆 𝗱𝗶𝘀𝘁𝗶𝗻𝗰𝘁𝗶𝗼𝗻: Primary prevents onset → secondary detects early → tertiary limits established damage.
Vaccination — Mechanism, Immune Memory and Delay to Protection
𝗔𝗻𝘁𝗶𝗴𝗲𝗻 𝗲𝘅𝗽𝗼𝘀𝘂𝗿𝗲: Vaccine presents weakened, inactivated or selected pathogen antigens without requiring the full natural disease. 𝗣𝗿𝗶𝗺𝗮𝗿𝘆 𝗿𝗲𝘀𝗽𝗼𝗻𝘀𝗲: Antigen recognition activates B cells (antibodies) and T cells (help and killing infected cells). 𝗠𝗲𝗺𝗼𝗿𝘆: Some activated B and T cells become memory cells → faster and stronger response at later exposure. 𝗧𝗶𝗺𝗲 𝘁𝗼 𝗽𝗿𝗼𝘁𝗲𝗰𝘁𝗶𝗼𝗻: Antibody production and immune memory take about 1 to several weeks; the person is not yet adequately protected immediately after vaccination. 𝗘𝘅𝗮𝗺𝗽𝗹𝗲: Influenza vaccine protection typically develops over about 2 weeks.
Active Immunity — IgG and Immune Memory
𝗦𝗼𝘂𝗿𝗰𝗲: The person’s own immune system responds to vaccination or natural infection. 𝗠𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺: B/T cell activation → antibody production + memory B and T cells. 𝗜𝗴𝗚: Usually develops later than IgM; commonly persists longer and contributes to longer-term humoral protection. 𝗢𝗻𝘀𝗲𝘁: Delayed: protection generally takes time to develop. 𝗗𝘂𝗿𝗮𝘁𝗶𝗼𝗻: Often months to years or longer; may require boosters. 𝗘𝘅𝗮𝗺𝗽𝗹𝗲: Hepatitis B vaccine. 𝗘𝘅𝗮𝗺 𝗱𝗶𝘀𝘁𝗶𝗻𝗰𝘁𝗶𝗼𝗻: IgG is not the definition of active immunity; active means the body generates the response.
Passive Immunity — Ready-Made Antibodies vs IgM
𝗗𝗲𝗳𝗶𝗻𝗶𝘁𝗶𝗼𝗻: Ready-made antibodies transferred from another source; recipient does not generate vaccine-induced memory from them. 𝗦𝗼𝘂𝗿𝗰𝗲𝘀: Maternal IgG across placenta; administered immunoglobulin (e.g., HBIG) or monoclonal antibody (nirsevimab). 𝗢𝗻𝘀𝗲𝘁: Immediate protection. 𝗗𝘂𝗿𝗮𝘁𝗶𝗼𝗻: Temporary; antibodies are gradually cleared; no immune memory generated by the transfer. 𝗜𝗴𝗠 𝗱𝗶𝘀𝘁𝗶𝗻𝗰𝘁𝗶𝗼𝗻: IgM often rises early in the body’s own PRIMARY response; it is NOT synonymous with passive immunity. 𝗘𝘅𝗮𝗺𝗽𝗹𝗲: HBIG at birth for certain newborns exposed to maternal hepatitis B, alongside active HBV vaccination.
Vaccination Timing and Catch-Up Through Age 17
𝗥𝗼𝘂𝘁𝗶𝗻𝗲 𝘁𝗶𝗺𝗶𝗻𝗴: Follow recommended age, minimum age and minimum intervals between doses; check history before giving catch-up doses. 𝗖𝗼𝗺𝗯𝗶𝗻𝗮𝘁𝗶𝗼𝗻: Some compatible vaccines can be given at the same visit at separate sites. 𝗖𝗮𝘁𝗰𝗵-𝘂𝗽: For children/adolescents through age 17 who missed doses, immigrated or have an incomplete series. 𝗠𝗮𝗶𝗻 𝗽𝗿𝗶𝗻𝗰𝗶𝗽𝗹𝗲: Do NOT restart a delayed series; continue missing doses using official minimum age and interval rules. 𝗦𝗽𝗲𝗰𝗶𝗮𝗹 𝘁𝗶𝗺𝗶𝗻𝗴: Some live vaccines and previous immunoglobulin administration require particular spacing.
Vaccination in Special Circumstances — Brief
𝗣𝗿𝗲𝗺𝗮𝘁𝘂𝗿𝗲 / 𝗟𝗕𝗪 𝗶𝗻𝗳𝗮𝗻𝘁𝘀: Usually vaccinate by chronological age, not corrected age; exceptions/adjustments include hepatitis B and some rotavirus situations. 𝗦𝗲𝘃𝗲𝗿𝗲 𝗶𝗺𝗺𝘂𝗻𝗼𝘀𝘂𝗽𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻: Avoid certain live vaccines; assess condition and treatment. 𝗜𝗹𝗹𝗻𝗲𝘀𝘀: Significant acute febrile or infectious illness may require postponement; mild illness or low fever below 38°C does not automatically require delay. 𝗢𝘁𝗵𝗲𝗿 𝗴𝗿𝗼𝘂𝗽𝘀: Pregnancy, breastfeeding, hospitalised children, steroid treatment, neurological conditions or prior exposures may require individual review.
Past Exam – 2024 Bet, Q49: When should premature infants or infants born with low birth weight (LBW) be vaccinated?
According to chronological age, except for the hepatitis B vaccine
Past Exam – 2023 Aleph, Q6: In which situation should a vaccine not be given to a child?
Acute infectious illness
Live Attenuated Vaccines — Type, Examples and Doses
𝗖𝗼𝗻𝘁𝗮𝗶𝗻𝘀: Living but weakened pathogen that can replicate to a limited degree. 𝗘𝗳𝗳𝗲𝗰𝘁: Strong, often long-lasting immune response, similar to natural infection. 𝗘𝘅𝗮𝗺𝗽𝗹𝗲𝘀: MMRV (measles, mumps, rubella, varicella); intranasal influenza spray. 𝗦𝗮𝗳𝗲𝘁𝘆: Usually avoid in severe immunosuppression; healthy household contacts may generally receive routine MMRV. 𝗪𝗵𝘆 𝗺𝘂𝗹𝘁𝗶𝗽𝗹𝗲 𝗱𝗼𝘀𝗲𝘀?: Some recipients fail to respond to dose 1 → dose 2 protects more people; not simply because the vaccine is weak. 𝗦𝗽𝗮𝗰𝗶𝗻𝗴 𝗿𝘂𝗹𝗲: Two different injectable live vaccines: same day OR at least 28 days (4 weeks) apart; oral/intranasal products can differ. 𝗡𝗼𝘁𝗲: If varicella-like rash develops after vaccination, seek advice on avoiding contact with severely immunocompromised people.
Past Exam – 2024 Aleph, Q45: Which of the following vaccines is a live attenuated vaccine?
MMRV — Measles, Mumps, Rubella, Varicella
Inactivated (Killed) Vaccines — Type, Examples and Doses
𝗖𝗼𝗻𝘁𝗮𝗶𝗻𝘀: Pathogen made noninfectious; cannot replicate or cause infection. 𝗘𝘅𝗮𝗺𝗽𝗹𝗲: IPV (inactivated polio vaccine); injected influenza vaccine. 𝗜𝗺𝗺𝘂𝗻𝗲 𝗿𝗲𝘀𝗽𝗼𝗻𝘀𝗲: Often weaker or less durable than live vaccines. 𝗪𝗵𝘆 𝗺𝘂𝗹𝘁𝗶𝗽𝗹𝗲 𝗱𝗼𝘀𝗲𝘀?: Primary series builds protective antibody concentrations; boosters restore protection when immunity wanes. 𝗦𝗮𝗳𝗲𝘁𝘆: Generally usable in immunocompromised patients, though responses may be reduced.
Toxoid Vaccines — Type and Examples
𝗖𝗼𝗻𝘁𝗮𝗶𝗻𝘀: Inactivated bacterial toxin (toxoid), not active toxin or the whole bacterium. 𝗠𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺: Antibodies neutralize the harmful toxin on later exposure. 𝗘𝘅𝗮𝗺𝗽𝗹𝗲𝘀: Tetanus and diphtheria components of DTaP. 𝗗𝗼𝘀𝗲𝘀: Primary series plus boosters as antibody levels wane. 𝗗𝗶𝘀𝘁𝗶𝗻𝗰𝘁𝗶𝗼𝗻: The pertussis component of DTaP is acellular/subunit, not a classic toxoid-only vaccine.
Past Exam – 2026 Aleph Pisgah, Q11: Which of the following vaccines is a toxoid vaccine?
DTaP — diphtheria and tetanus
Subunit Vaccines — Type and Examples
𝗖𝗼𝗻𝘁𝗮𝗶𝗻𝘀: Selected antigens (such as pathogen proteins), not the entire organism. 𝗠𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺: Recognizable antigen stimulates an immune response without pathogen replication. 𝗘𝘅𝗮𝗺𝗽𝗹𝗲: Acellular pertussis component of DTaP. 𝗕𝗲𝗻𝗲𝗳𝗶𝘁: Fewer unnecessary components and often a favorable safety profile. 𝗗𝗼𝘀𝗲𝘀: May require multiple doses, adjuvants and boosters for durable protection.
Conjugate Vaccines — Type and Examples
𝗣𝗿𝗼𝗯𝗹𝗲𝗺: Young infants respond poorly to the polysaccharide capsule of some encapsulated bacteria. 𝗠𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺: Bacterial polysaccharide attached to a carrier protein → T-cell-dependent response and stronger immune memory. 𝗘𝘅𝗮𝗺𝗽𝗹𝗲: Pneumococcal conjugate vaccine (PCV; e.g., Prevnar). 𝗣𝗿𝗼𝘁𝗲𝗰𝘁𝘀 𝗮𝗴𝗮𝗶𝗻𝘀𝘁: Invasive pneumococcal infection; also reduces some pneumonia and otitis media. 𝗗𝗼𝘀𝗲𝘀: Given in an age-based infant series to establish and maintain protection.
Past Exam – 2024 Bet, Q15: Which vaccine is a preventive factor against otitis media?
Prevnar 13
Hepatitis B — Disease and Infant Vaccination
𝗗𝗶𝘀𝗲𝗮𝘀𝗲: HBV infects the liver → chronic hepatitis, cirrhosis, liver failure and hepatocellular carcinoma. 𝗪𝗵𝘆 𝗮𝘁 𝗯𝗶𝗿𝘁𝗵?: Perinatal infection progresses to chronic infection in about 90% of infants; early vaccination reduces this risk. 𝗟𝗼𝗻𝗴-𝘁𝗲𝗿𝗺 𝗿𝗶𝘀𝗸: Lecture: about 1 in 4 chronically infected during infancy may eventually die from HBV-related complications. 𝗦𝗰𝗵𝗲𝗱𝘂𝗹𝗲: Birth → 1 month → 6 months (routine Israel series). 𝗠𝗮𝘁𝗲𝗿𝗻𝗮𝗹 𝗛𝗕𝗩 𝗲𝘅𝗽𝗼𝘀𝘂𝗿𝗲: At-risk newborn may receive HBIG (immediate passive protection) PLUS hepatitis B vaccine (active long-term protection).
Past Exam – 2026 Aleph Pisgah, Q10: The hepatitis B vaccine is administered at which times?
Birth, 1 month, and 6 months
RSV — Virus, Passive Immunisation, Schedule and Side Effects
𝗥𝗦𝗩: Respiratory syncytial virus; common cause of bronchiolitis and pneumonia in infants, especially in autumn/winter. 𝗛𝗶𝗴𝗵-𝗿𝗶𝘀𝗸: Prematurity, chronic lung disease and congenital heart disease; most children encounter RSV by age 2. 𝗣𝗿𝗼𝗱𝘂𝗰𝘁: Beyfortus (nirsevimab): long-acting monoclonal antibody, given IM in thigh; PASSIVE immunisation, not conventional active vaccine. 1 𝗦𝗲𝗽–31 𝗠𝗮𝗿 𝗯𝗶𝗿𝘁𝗵𝘀: Give before hospital discharge after birth. 1 𝗔𝗽𝗿–31 𝗔𝘂𝗴 𝗯𝗶𝗿𝘁𝗵𝘀: Give before RSV season, in late summer/early autumn, generally through Tipat Halav. 𝗦𝗲𝗰𝗼𝗻𝗱 𝘀𝗲𝗮𝘀𝗼𝗻: May be offered to certain high-risk infants/toddlers. 𝗘𝗳𝗳𝗲𝗰𝘁𝘀: Possible injection-site redness, swelling/pain or rash; protection is immediate but temporary.
Past Exam – 2024 Bet, Q14: What is the main cause of bronchiolitis in children?
Respiratory syncytial virus (RSV)
Past Exam – 2024 Aleph, Q9: What is the treatment goal for an infant with bronchiolitis?
Respiratory rate below 60 breaths per minute
Past Exam – 2025 Aleph, Q40: What type of isolation is required when caring for a child with respiratory syncytial virus (RSV)?
Contact isolation
Israel Routine Childhood Vaccinations — Schedule Summary (2026)
𝗕𝗶𝗿𝘁𝗵: Hepatitis B; seasonal RSV nirsevimab according to birth month. 1 𝗺𝗼𝗻𝘁𝗵: Hepatitis B. 2 𝗺𝗼𝗻𝘁𝗵𝘀: Pentavalent (DTaP-IPV-Hib), rotavirus and pneumococcal conjugate (PCV); first pentavalent dose may be advanced to 6 weeks in some guidance. 4 𝗺𝗼𝗻𝘁𝗵𝘀: Pentavalent, rotavirus and PCV. 6 𝗺𝗼𝗻𝘁𝗵𝘀: Pentavalent, rotavirus and hepatitis B. 12 𝗺𝗼𝗻𝘁𝗵𝘀: Pentavalent booster, PCV booster and first MMRV. 18 𝗺𝗼𝗻𝘁𝗵𝘀: Hepatitis A; second MMRV for children born from 1 Jan 2025 (from 1 Jul 2026 onward). 24 𝗺𝗼𝗻𝘁𝗵𝘀: Second hepatitis A dose. 𝗦𝗰𝗵𝗼𝗼𝗹 𝘆𝗲𝗮𝗿𝘀: Diphtheria/tetanus/pertussis ± polio boosters, influenza and HPV per current programme.
Measles (Rubeola) — Virus, Transmission and Epidemiology
𝗡𝗮𝗺𝗲: Measles = RUBEOLA (חצבת), NOT rubella (German measles). 𝗖𝗮𝘂𝘀𝗲: Highly contagious RNA virus. 𝗧𝗿𝗮𝗻𝘀𝗺𝗶𝘀𝘀𝗶𝗼𝗻: Airborne spread; about 90% of susceptible close contacts may become infected. 𝗜𝗻𝗰𝘂𝗯𝗮𝘁𝗶𝗼𝗻: Lecture: 6–21 days. 𝗖𝗼𝗻𝘁𝗮𝗴𝗶𝗼𝘂𝘀 𝗽𝗲𝗿𝗶𝗼𝗱: About 4 days BEFORE to 4 days AFTER rash onset. 𝗜𝗺𝗺𝘂𝗻𝗶𝘁𝘆: Natural infection often gives lifelong immunity but can cause serious complications; 2 vaccine doses give about 97% protection. 𝗣𝘂𝗯𝗹𝗶𝗰 𝗵𝗲𝗮𝗹𝘁𝗵: Around 95% population immunity is needed to interrupt sustained transmission.
Measles — Clinical Presentation and Rash
𝗣𝗿𝗼𝗱𝗿𝗼𝗺𝗲: Fever + 3 Cs: cough, coryza (runny nose), conjunctivitis. 𝗕𝗲𝗳𝗼𝗿𝗲 𝗿𝗮𝘀𝗵: Koplik spots: small white oral lesions, characteristic of measles. 𝗥𝗮𝘀𝗵: Maculopapular: red flat macules + raised papules, may merge. 𝗦𝗽𝗿𝗲𝗮𝗱: Begins face/hairline/behind ears → descends to trunk and limbs. 𝗞𝗲𝘆 𝗽𝗼𝗶𝗻𝘁: The child is contagious BEFORE rash appears.
Past Exam – 2022 Aleph, Q15: Which viral disease begins with upper respiratory tract inflammation and conjunctivitis, followed several days later by a rash on the body?
Measles
Measles — Complications and Immune Amnesia
𝗥𝗮𝘁𝗲: Lecturer: complications in approximately 30% of cases. 𝗚𝗜: Diarrhea. 𝗘𝗮𝗿 𝗮𝗻𝗱 𝗮𝗶𝗿𝘄𝗮𝘆: Otitis media, laryngotracheobronchitis. 𝗟𝘂𝗻𝗴𝘀: Pneumonia (major cause of severe disease). 𝗖𝗡𝗦: Encephalitis → neurological injury or death. 𝗜𝗺𝗺𝘂𝗻𝗲 𝗮𝗺𝗻𝗲𝘀𝗶𝗮: Measles can damage existing immune memory → susceptibility to other infections for months to years (lecture: up to 3 years).
Measles — MMRV Prevention, Outbreak Data and Postexposure
𝗥𝗼𝘂𝘁𝗶𝗻𝗲 𝗠𝗠𝗥𝗩: Measles, mumps, rubella and varicella; first dose 12 months. 𝗦𝗲𝗰𝗼𝗻𝗱 𝗱𝗼𝘀𝗲 — 2026 𝘂𝗽𝗱𝗮𝘁𝗲: 18 months for children born from 1 Jan 2025; replaces the former first-grade second dose. 𝗢𝘂𝘁𝗯𝗿𝗲𝗮𝗸/𝘁𝗿𝗮𝘃𝗲𝗹: An extra measles-containing dose may be recommended at age 6–11 months; it does NOT replace the 2 routine doses. 𝗔𝗳𝘁𝗲𝗿 𝗲𝘅𝗽𝗼𝘀𝘂𝗿𝗲: Vaccine within 72 hours for eligible susceptible contacts; immunoglobulin within 6 days for selected high-risk contacts. 2025 𝗼𝘂𝘁𝗯𝗿𝗲𝗮𝗸 𝗰𝗵𝗮𝗿𝘁: About 80% of cases unvaccinated, 14% partially vaccinated, 6% fully vaccinated; ages 1–5 were the largest affected group. 𝗜𝗻𝘁𝗲𝗿𝗽𝗿𝗲𝘁𝗮𝘁𝗶𝗼𝗻: The 6% describes share of all reported cases, NOT infection risk in vaccinated children or necessarily the 1–5 subgroup.
Pertussis (Whooping Cough) — Organism, Symptoms and Diagnosis
𝗖𝗮𝘂𝘀𝗲: Bordetella pertussis: highly contagious bacterial respiratory infection. 𝗧𝗿𝗮𝗻𝘀𝗺𝗶𝘀𝘀𝗶𝗼𝗻: Respiratory droplets/secretions during coughing or sneezing; high household spread. 𝗦𝘆𝗺𝗽𝘁𝗼𝗺𝘀: Repeated severe paroxysmal cough → inspiratory “whoop”; post-tussive vomiting may occur. 𝗬𝗼𝘂𝗻𝗴 𝗶𝗻𝗳𝗮𝗻𝘁𝘀: May present with apnea, cyanosis or respiratory distress WITHOUT classic whoop. 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝘀: Nasopharyngeal swab/aspirate for PCR or bacterial culture. 𝗖𝗼𝗺𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀: Pneumonia, seizures, conjunctival hemorrhage, encephalopathy, death. 𝗣𝗿𝗲𝗰𝗮𝘂𝘁𝗶𝗼𝗻𝘀: Droplet isolation.
Pertussis Vaccination — Infants, Boosters and Pregnancy
𝗩𝗮𝗰𝗰𝗶𝗻𝗲: Acellular pertussis in DTaP (childhood) and Tdap (pregnancy/boosters). 𝗥𝗼𝘂𝘁𝗶𝗻𝗲 𝗶𝗻𝗳𝗮𝗻𝘁 𝘀𝗲𝗿𝗶𝗲𝘀: 2, 4, 6 and 12 months; first pentavalent dose can be given at 6 weeks under current Israeli advice. 𝗦𝗰𝗵𝗼𝗼𝗹 𝗯𝗼𝗼𝘀𝘁𝗲𝗿𝘀: Grade 2 (Grade 1 in certain northern/southern districts) and Grade 8. 𝗣𝗿𝗲𝗴𝗻𝗮𝗻𝗰𝘆: Tdap during EACH pregnancy, typically weeks 27–36 (lecture: 28–36). 𝗪𝗵𝘆 𝗶𝗻 𝗽𝗿𝗲𝗴𝗻𝗮𝗻𝗰𝘆?: Maternal IgG crosses placenta → immediate passive protection until infant vaccine doses are effective. 𝗪𝗵𝘆 𝗯𝗼𝗼𝘀𝘁𝗲𝗿𝘀?: Pertussis immunity wanes over time.
Vaccine Preparation — Cold Chain and IM Injection Site
𝗦𝘁𝗼𝗿𝗮𝗴𝗲: Maintain cold chain at 2–8°C in refrigerator; inadequate storage can reduce effectiveness. 𝗜𝗻𝗳𝗮𝗻𝘁 𝗜𝗠 𝘀𝗶𝘁𝗲: Anterolateral thigh — vastus lateralis muscle. 𝗪𝗵𝘆 𝘁𝗵𝗶𝘀 𝗺𝘂𝘀𝗰𝗹𝗲?: Large and well developed in infants, suitable for safe IM injection.
Past Exam – 2023 Bet, Q28: What is the appropriate temperature range in degrees Celsius for storing vaccines in a refrigerator?
2–8°C
Past Exam – 2022 Aleph, Q39: What is the recommended injection site for administering a vaccine to a 6-month-old infant?
Anterolateral aspect of the thigh
Reporting Adverse Events After Immunisation — Israel
𝗥𝗲𝗽𝗼𝗿𝘁𝗮𝗯𝗹𝗲 𝗲𝘅𝗮𝗺𝗽𝗹𝗲𝘀 𝗶𝗻 𝗹𝗲𝗰𝘁𝘂𝗿𝗲: Local redness or swelling GREATER THAN 5 cm; fever above 38°C; allergic reactions; anaphylaxis. 𝗣𝗮𝘁𝗶𝗲𝗻𝘁: Record identifying information and relevant clinical history. 𝗩𝗮𝗰𝗰𝗶𝗻𝗲: Name/product, date, dose if available, and batch/lot number (אצווה). 𝗘𝘃𝗲𝗻𝘁: Description, severity, time of onset and progression. 𝗖𝗼𝗻𝘁𝗲𝘅𝘁: Previous reactions and treatment provided. 𝗡𝗼𝘁𝗲: An event after vaccination does not automatically prove that vaccination caused it.
Anaphylaxis Following Vaccination — Definition and Differentiation
𝗗𝗲𝗳𝗶𝗻𝗶𝘁𝗶𝗼𝗻: Rapid-onset, potentially life-threatening systemic hypersensitivity involving airway/breathing and/or circulation. 𝗧𝗶𝗺𝗶𝗻𝗴: Usually within minutes to about 1 hour after exposure; respond urgently. 𝗔𝗻𝗮𝗽𝗵𝘆𝗹𝗮𝘅𝗶𝘀: Often hives/flushing/swelling + wheeze/stridor or hypotension; may have NO rash. 𝗩𝗮𝘀𝗼𝘃𝗮𝗴𝗮𝗹 𝘀𝘆𝗻𝗰𝗼𝗽𝗲: Pallor, cool sweat, usually slow pulse; breathing usually normal. 𝗔𝗻𝘅𝗶𝗲𝘁𝘆: Hyperventilation, typically maintained BP, without true airway obstruction. 𝗟𝗼𝗰𝗮𝗹 𝗮𝗹𝗹𝗲𝗿𝗴𝘆: Local rash/swelling without systemic respiratory or cardiovascular compromise. 𝗡𝘂𝗿𝘀𝗶𝗻𝗴 𝗽𝗿𝗶𝗼𝗿𝗶𝘁𝘆: Do not dismiss sudden respiratory or circulatory compromise as fainting or anxiety.
Anaphylaxis — Signs and Symptoms (Skin May Be Absent)
𝗦𝗸𝗶𝗻/𝗺𝘂𝗰𝗼𝘀𝗮: Urticaria, itching, flushing, angioedema; may be completely absent. 𝗔𝗶𝗿𝘄𝗮𝘆: Tongue/throat swelling, hoarseness, stridor, airway obstruction. 𝗕𝗿𝗲𝗮𝘁𝗵𝗶𝗻𝗴: Dyspnea, wheeze/bronchospasm, reduced oxygen saturation. 𝗖𝗶𝗿𝗰𝘂𝗹𝗮𝘁𝗶𝗼𝗻: Hypotension, weak rapid pulse, collapse/shock. 𝗚𝗜: Abdominal pain, vomiting. 𝗔𝘀𝘀𝗲𝘀𝘀𝗺𝗲𝗻𝘁: Rapid onset and multisystem signs; monitor airway, SpO₂, breathing effort, pulse and BP. 𝗖𝗿𝗶𝘁𝗶𝗰𝗮𝗹: Severe airway or cardiovascular signs can establish suspicion even without hives or rash.
Anaphylaxis — Emergency Management
Epinephrine in Anaphylaxis — Mechanism and Route
𝗙𝗶𝗿𝘀𝘁-𝗹𝗶𝗻𝗲: Epinephrine (adrenaline) IM into anterolateral thigh; do NOT delay. 𝗔𝗹𝗽𝗵𝗮 𝗿𝗲𝗰𝗲𝗽𝘁𝗼𝗿𝘀: Vasoconstriction → raises BP and reduces airway mucosal edema. 𝗕𝗲𝘁𝗮-1 𝗿𝗲𝗰𝗲𝗽𝘁𝗼𝗿𝘀: Increases heart rate and contractility → supports circulation. 𝗕𝗲𝘁𝗮-2 𝗿𝗲𝗰𝗲𝗽𝘁𝗼𝗿𝘀: Bronchodilation → improves airflow. 𝗗𝗼𝘀𝗶𝗻𝗴 𝗽𝗿𝗶𝗻𝗰𝗶𝗽𝗹𝗲: Weight-based dosing preferred; age-based fallback only if weight cannot be determined quickly, per protocol. 𝗔𝘃𝗼𝗶𝗱: Subcutaneous route is NOT recommended; IV epinephrine is NOT routine initial treatment. 𝗗𝗼 𝗻𝗼𝘁 𝘀𝘂𝗯𝘀𝘁𝗶𝘁𝘂𝘁𝗲: Antihistamines and corticosteroids cannot replace or delay epinephrine.
HBV
𝗘𝗻𝗴𝗹𝗶𝘀𝗵: Hepatitis B Vaccine 𝗛𝗲𝗯𝗿𝗲𝘄: חיסון נגד דלקת כבד נגיפית B (צהבת B) 𝗚𝗶𝘃𝗲𝗻: At birth → 1 month → 6 months.
IPV
𝗘𝗻𝗴𝗹𝗶𝘀𝗵: Inactivated Poliovirus Vaccine (Polio) 𝗛𝗲𝗯𝗿𝗲𝘄: חיסון מומת נגד שיתוק ילדים (פוליו) 𝗚𝗶𝘃𝗲𝗻: 2 months → 4 months → 6 months → 12 months → 7 years (Grade 2).
DTaP / Tdap
𝗘𝗻𝗴𝗹𝗶𝘀𝗵: Diphtheria, Tetanus and acellular Pertussis (Whooping Cough) Vaccine 𝗛𝗲𝗯𝗿𝗲𝘄: חיסון נגד אסכרה (דיפתריה), פלצת (טטנוס) ושעלת (אסלולרית) 𝗗𝗧𝗮𝗣 — 𝗽𝗲𝗱𝗶𝗮𝘁𝗿𝗶𝗰: Higher-dose diphtheria and pertussis antigens; given at 2 → 4 → 6 → 12 months. 𝗧𝗱𝗮𝗽 — 𝗯𝗼𝗼𝘀𝘁𝗲𝗿: Reduced-dose diphtheria and pertussis antigens (lowercase d and p) for older ages; 7 years (Grade 2) and 13–14 years (Grade 8).
Hib
𝗘𝗻𝗴𝗹𝗶𝘀𝗵: Haemophilus influenzae type b Vaccine 𝗛𝗲𝗯𝗿𝗲𝘄: חיסון נגד המופילוס אינפלואנזה מסוג b 𝗚𝗶𝘃𝗲𝗻: 2 months → 4 months → 6 months → 12 months.
MMR
𝗘𝗻𝗴𝗹𝗶𝘀𝗵: Measles, Mumps and Rubella Vaccine 𝗛𝗲𝗯𝗿𝗲𝘄: חיסון נגד חצבת, חזרת ואדמת 𝗙𝗶𝗿𝘀𝘁 𝗱𝗼𝘀𝗲: 12 months (with Var, as combined MMRV). 𝗦𝗲𝗰𝗼𝗻𝗱 𝗱𝗼𝘀𝗲 — 𝗯𝗼𝗿𝗻 𝗳𝗿𝗼𝗺 1 𝗝𝗮𝗻 2025: 18 months (with Var). 𝗦𝗲𝗰𝗼𝗻𝗱 𝗱𝗼𝘀𝗲 — 𝗯𝗼𝗿𝗻 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 31 𝗗𝗲𝗰 2024: 6 years / Grade 1 (with Var).
Var
𝗘𝗻𝗴𝗹𝗶𝘀𝗵: Varicella (Chickenpox) Vaccine 𝗛𝗲𝗯𝗿𝗲𝘄: חיסון נגד אבעבועות רוח 𝗙𝗶𝗿𝘀𝘁 𝗱𝗼𝘀𝗲: 12 months (with MMR, as combined MMRV). 𝗦𝗲𝗰𝗼𝗻𝗱 𝗱𝗼𝘀𝗲 — 𝗯𝗼𝗿𝗻 𝗳𝗿𝗼𝗺 1 𝗝𝗮𝗻 2025: 18 months (with MMR). 𝗦𝗲𝗰𝗼𝗻𝗱 𝗱𝗼𝘀𝗲 — 𝗯𝗼𝗿𝗻 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 31 𝗗𝗲𝗰 2024: 6 years / Grade 1 (with MMR).
HAV
𝗘𝗻𝗴𝗹𝗶𝘀𝗵: Hepatitis A Vaccine 𝗛𝗲𝗯𝗿𝗲𝘄: חיסון נגד דלקת כבד נגיפית A (צהבת A) 𝗙𝗶𝗿𝘀𝘁 𝗱𝗼𝘀𝗲: 18 months. 𝗦𝗲𝗰𝗼𝗻𝗱 𝗱𝗼𝘀𝗲 — 𝗯𝗼𝗿𝗻 𝗳𝗿𝗼𝗺 1 𝗝𝗮𝗻 2025: 6 years / Grade 1, according to the supplied September 2026 chart. 𝗦𝗲𝗰𝗼𝗻𝗱 𝗱𝗼𝘀𝗲 — 𝗯𝗼𝗿𝗻 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 31 𝗗𝗲𝗰 2024: 24 months.
PCV20
𝗘𝗻𝗴𝗹𝗶𝘀𝗵: 20-valent Pneumococcal Conjugate Vaccine 𝗛𝗲𝗯𝗿𝗲𝘄: חיסון מצומד נגד חיידק הפנאומוקוק (20 זנים) 𝗚𝗶𝘃𝗲𝗻: 2 months → 4 months → 12 months.
Rota
𝗘𝗻𝗴𝗹𝗶𝘀𝗵: Rotavirus Vaccine 𝗛𝗲𝗯𝗿𝗲𝘄: חיסון נגד נגיף הרוטה 𝗚𝗶𝘃𝗲𝗻: 2 months → 4 months → 6 months (oral vaccine).
HPV
𝗘𝗻𝗴𝗹𝗶𝘀𝗵: Human Papillomavirus Vaccine 𝗛𝗲𝗯𝗿𝗲𝘄: חיסון נגד נגיף הפפילומה האנושי 𝗚𝗶𝘃𝗲𝗻: 13–14 years / Grade 8; 2 doses according to the supplied chart.
Flu
𝗘𝗻𝗴𝗹𝗶𝘀𝗵: Influenza Vaccine 𝗛𝗲𝗯𝗿𝗲𝘄: חיסון נגד שפעת 𝗚𝗶𝘃𝗲𝗻: Every year (seasonal vaccination, from 6 months of age). 𝗦𝗰𝗵𝗼𝗼𝗹-𝗯𝗮𝘀𝗲𝗱 𝗱𝗼𝘀𝗲𝘀 𝘀𝗵𝗼𝘄𝗻 𝗶𝗻 𝗰𝗵𝗮𝗿𝘁: 7 years / Grade 2 → 8 years / Grade 3 → 9 years / Grade 4.
RSV
𝗘𝗻𝗴𝗹𝗶𝘀𝗵: Respiratory Syncytial Virus (RSV) immunisation — Beyfortus (nirsevimab) 𝗛𝗲𝗯𝗿𝗲𝘄: חיסון סביל נגד נגיף RSV (הנגיף הנשימתי הסינציאלי) 𝗧𝘆𝗽𝗲: Long-acting monoclonal antibody → immediate PASSIVE protection, not a conventional active vaccine. 𝗕𝗼𝗿𝗻 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿–𝗠𝗮𝗿𝗰𝗵: Given at birth / before hospital discharge during the RSV season. 𝗕𝗼𝗿𝗻 𝗔𝗽𝗿𝗶𝗹–𝗔𝘂𝗴𝘂𝘀𝘁: Given at Tipat Halav before the next RSV season, usually at its start. 𝗛𝗶𝗴𝗵-𝗿𝗶𝘀𝗸 𝗰𝗵𝗶𝗹𝗱𝗿𝗲𝗻: May receive protection during the second RSV season (up to 2 years in the chart)